Incyclix Bio

Incyclix Bio is a biotechnology startup based in the United States, founded in 2020. The company is focused on advancing precision treatments that target the aberrant proliferation driving many cancers, with a slogan of "Regaining Cell Cycle Control". They are scientific leaders in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast, and lung cancers. Their lead compound, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor, is nearing the clinical stage. In March 2022, Incyclix Bio secured a significant $30.00M Series B investment from prominent investors including RA Capital Management, Boxer Capital, and Eshelman Ventures. The startup is headquartered in Research Triangle Park, NC and is founded by pioneers in CDK inhibitor discovery, research, and development. Incyclix Bio's innovative approach to targeting cell cycle control in cancer treatment, coupled with its strong financial backing from reputable investors, positions the company for potential future growth and impact in the biotechnology and healthcare industries.